SERIES
KRAS Deep Dive
The decades-long breakthrough, and what comes next
KRAS was long considered “undruggable” — the flagship of intractable cancer drivers. The emergence of Sotorasib and Adagrasib opened the door, and next-generation targets are now at the center of the competitive landscape. This series decodes KRAS past, present, and future.
📋 Reading Path
- Intro: Why Was KRAS Called Undruggable
- G12C: Emergence of Inhibitors and Clinical Data
- Resistance: Resistance Mechanisms
- Pan-KRAS: Development of Pan-KRAS Inhibitors
- Future: Next-Gen Strategies Against Resistance
📚 All Articles in This Series
🔗 Related Series
Bispecific Antibody Series / ADC (Antibody-Drug Conjugate) Series / CAR-T Series / Oncology Approval News